AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05398679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tedizolid Oral Tablet
Description: 200 mg tedizolid (maximum x day)
Study NCT05398679 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tedizolid Injection
Description: 200 mg (maximum x day)
Study NCT05398679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin Capsules
Description: 1 gr/6 hours (4 g x day)
Study NCT05398679 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: 1 gr/6 hours (4 g x day) Intravenous
Study NCT05398679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefaclor Capsules
Description: 2 gr/day
Study NCT04733651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hospital standard of care for COVID-19
Description: Standard care for COVID-19 as per the hospital guidelines
Study NCT04733651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hospital standard of care for COVID-19
Description: Standard care for COVID-19 as per the hospital guidelines
Study NCT04733651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoquercetin
Description: Daily 1000 mg Isoquercetin as 4 capsules
Study NCT06218238 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Powered prosthetic knee joint
Description: Subjects will be fitted and trained on the Ossur Power Knee. An accommodation of 1 month will be provided prior to evaluation with the knee joint.
Study NCT06218238 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional prosthetic knee joint
Description: Subjects will be fitted and trained on the Ossur Rheo XC Knee. An accommodation of 1 month will be provided prior to evaluation with the knee joint.
Study NCT05322174 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baby Sleep
Description: See arm description
Study NCT05216471 — intervention group
Intervention type: RADIATION
Intervention: chest X-ray
Description: Chest Xray : postero-anterior view ,digital high resolution X-ray or ,full inspiratory
Study NCT05433597 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-fu
Description: 5-fu: 200mg/m2/d, continuous intravenous infusion on the 1st to 30th day of each cycle.
Study NCT05433597 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fu
Description: 5-fu: 200mg/m2/d, continuous intravenous infusion on the 1st to 30th day of each cycle.
Study NCT05433597 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin: 80mg/m2, used on the 1st and 28th day of each cycle.
Study NCT05433597 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin: 80mg/m2, used on the 1st and 28th day of each cycle.
Study NCT05433597 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiotherapy
Description: Radiotherapy: Radiotherapy was initiated on day 15 of the first cycle of chemotherapy . GTV: 6810cGy (227 cGy/30f) Or 6996 cGy (212 cGy/ 33F); CTV: 5400-6000 cGy (180-200 cGy/f); Radiotherapy once a day, 5 times a week, a total of 30-33 times, a total of about 6 weeks.
Study NCT05433597 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Radiotherapy: Radiotherapy was initiated on day 15 of the first cycle of chemotherapy . GTV: 6810cGy (227 cGy/30f) Or 6996 cGy (212 cGy/ 33F); CTV: 5400-6000 cGy (180-200 cGy/f); Radiotherapy once a day, 5 times a week, a total of 30-33 times, a total of about 6 weeks.
Study NCT05433597 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TNF
Description: TNF (recombinant human tumor necrosis factor for injection) : 1 million IU (BSA\<2.0m2) or 1.5 million IU (BSA≥2.0m2), dissolved in normal saline 1-2mL, intramuscular, QD, 30 days in the first and third months, once a day.
Study NCT05433597 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: 1-2ml normal saline, intramuscular injection, QD, once a day, 30 days in the first and third months.
Study NCT04747028 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Dmf score
Description: A chart to calculate the caries index
Study NCT05800275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib Oral Tablet
Description: 300 mg, twice daily
Study NCT05800275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine tablets
Description: 1000 mg/m², twice daily on days 1-14 of each 21-day cycle
Study NCT05800275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Injection
Description: Intrathecal by lumbar puncture or Ommaya Reservoir, 150 mg weekly
Study NCT04946331 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical impedance tomography system
Description: Which can use the applied current and measurement voltage through the body surface electrode group, and use the reconstruction algorithm to construct an image imaging system that exceeds the cross-sectional, which can provide images of the internal physiological changes of the chest contour, in order to quantify the changes in lung function caused by rib fractures.
Study NCT05322174 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Baby Care
Description: See arm description
Study NCT06199453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium (177Lu) vipivotide tetraxetan
Description: 6 cycles of lutetium (177Lu) vipivotide-tetraxetan with an activity of 200 mCi (7.4 GBq) at intervals of 6 weeks
Study NCT06584019 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Range Of Motion applied group
Description: Range Of Motion was applied once a day for approximately 20 minutes for 5 days.
Study NCT04924153 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: Administered as specified in the treatment arm.
Study NCT06029699 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high flow nasal cannula
Description: device are used for weaning patients after mechanical ventilation extubation
Study NCT06029699 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: non invasive positive pressure ventilation
Description: device are used for weaning patients after mechanical ventilation extubation
Study NCT04726943 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency Energy Applications
Description: RF energy applications to the atrial edge of a leak resulting from incomplete LAA occlusion
Study NCT05275309 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exploration of optimal PEEP in supine and prone position
Description: 1. General anesthesia is done in routine manner~2. A sensor for electrical impedance tomography (EIT) is applied around the patient's chest.~3. In supine position, lung recruitment maneuver is done, followed by decremental PEEP trial. Based on EIT parameter, optimal PEEP which induces minimal overdistension and collapse of lungs is determined.~4. One hour after prone position, optimal PEEP is determined again.
Study NCT05237947 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed
Description: Given IM
Study NCT05237947 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05237947 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05237947 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Human Papillomavirus Bivalent Vaccine
Description: Given IM
Study NCT05237947 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Human Papillomavirus Nonavalent Vaccine
Description: Given IM
Study NCT05282433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib
Description: Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular Carcinoma
Study NCT05512273 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piezosurgery assisted osteotomy
Description: Sequential osteotomy drilling was done using mectron piezosurgery implant drilling protocol
Study NCT05512273 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional drilling osteotomy
Description: bone osteotomy for implant placement was done following the BEGO Semados RS/RSX TrayPlus conventional drilling
Study NCT06108830 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esketamine
Description: Patients undergoing gastroenteroscopies were given propofol 2 to 3mg/kg and esketamine 0.2mg/kg before the procedure began
Study NCT06108830 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remimazolam
Description: Patients undergoing gastroenteroscopies were given propofol 2 to 3mg/kg and remimazolam 0.15mg/kg before the procedure began
Study NCT06108830 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esketamine and remimazolam
Description: Patients undergoing gastroenteroscopies were given propofol 2 to 3mg/kg and remimazolam 0.15mg/kg before the procedure began
Study NCT06108830 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Patients undergoing gastroenteroscopies were given propofol 2-3mg/kg and 10ml 0.9% saline before the procedure began
Study NCT04245384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-based dietetic treatment with video calls
Description: The dietitian meets the patient through video calls, no physical meetings
Study NCT05740332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol hand sanitizer foam
Description: 1mL of alcohol foam hand sanitizer automatically dispensed into hands, spread over hands and rubbed until dry.~Other Name: Medline Spectrum™ Advanced Hand Sanitizer Foam (70%)
Study NCT04245384 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional dietetic treatment
Description: The dietitian meets the patient through physical meetings
Study NCT05691010 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy
Description: After cycles 1, 2, 3 or 4 of chemotherapy, patients will receive IMRT to the vaginal cuff and pelvic lymph nodes with a total dose of 25 Gy delivered in 5 daily fractions of 5 Gy
Study NCT05453435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: All patients enrolled in the study will accept entecavir prophylaxis that initiates within 1 week before the first course of CD20 monoclonal antibody therapy, and continues until 6 months after completing CD20 monoclonal antibody therapy.
Study NCT05691010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Patients enrolled in this trial will receive chemotherapy with carboplatin IV AUC 5 at the discretion of the treating investigator plus paclitaxel 175 mg/m2 every 21 days for 6 cycles
Study NCT05691010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Patients enrolled in this trial will receive chemotherapy with carboplatin IV AUC 5 at the discretion of the treating investigator plus paclitaxel 175 mg/m2 every 21 days for 6 cycles
Study NCT05504551 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided superficial cervical plexus block
Description: SCP block is given using high frequency linear ultrasound probe connected to an ultrasound machine to visualize SCP posterior to the midpoint of SCM muscle. Once SCP is identified, a combination of 5 ml bupivacaine (0.5%) and 5 ml lidocaine (2%) are injected after negative aspiration followed by injection of 1 ml to confirm the area, using a 22 gauge B-bevel needle Echogenic Needle.
Study NCT05504551 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: ultrasound guided superficial cervical plexus block
Description: SCP block is given using high frequency linear ultrasound probe connected to an ultrasound machine to visualize SCP posterior to the midpoint of SCM muscle. Once SCP is identified, a combination of 5 ml bupivacaine (0.5%) and 5 ml lidocaine (2%) are injected after negative aspiration followed by injection of 1 ml to confirm the area, using a 22 gauge B-bevel needle Echogenic Needle.
Study NCT05827315 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Echocardiography will be performed by BSE accredited echocardiographers in all 175 patients preoperatively and on day 2-4 postoperatively.
Study NCT05827315 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: T1 Cardiovascular Magnetic Resonance
Description: T1 CMR will be performed in 10 patients from each of the 5 surgical groups (50 patients in total) preoperatively and on day 2-4 postoperatively.
Study NCT05827315 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Right heart catheterisation and coronary sinus blood sampling
Description: 10 patients from the thoracic surgical group will undergo right heart catheterisation and coronary sinus blood sampling.
Study NCT05500742 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Coenzyme Q10
Description: Soft 100 mg capsules containing coenzyme Q10 in vegetable oil provided by Pharma Nord
Study NCT05500742 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Selenium
Description: 100 mcg tablets provided by Pharma Nord
Study NCT05500742 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Resveratrol
Description: 350 mg capsules provided by NOW Foods
Study NCT06193382 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PCIT
Description: Participants will receive the adapted Pocket PCIT Online via a web-based learning platform for up to 5 weeks. Participants will engage in this intervention weekly for about 1 hour per week. During engaging with the adapted Pocket PCIT Online version of PCIT, caregivers will learn positive parenting skills to increase the warmth of the parent-child relationship as well as strategies to effectively set limits. Participants will also participate in 15-minute check-in phone calls with a therapist each week throughout the course of treatment.
Study NCT05500742 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: TA-65 MD
Description: 100 unit capsules provided by TA Sciences
Study NCT04750902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.24% Sodium Fluoride Dentifrice
Description: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
Study NCT04750902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.5% Arginine Dentifrice
Description: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
Study NCT04750902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4.0% Arginine Dentifrice
Description: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
Study NCT05500742 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-1
Description: Soft capsules containing vegetable oil, externally identical to coenzyme Q10 capsules, provided by Pharma Nord
Study NCT05500742 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-2
Description: Tablets containing excipients, externally identical to selenium tablets, provided by Pharma Nord
Study NCT06187805 — intervention group
Intervention type: DEVICE
Intervention: OSSIX Volumax
Description: OSSIX Volumax is used in combination with autogenous bone collected during preparation of the implant osteotomy.
Study NCT04877457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: The first course of ocrelizumab will be administered as two 300 mg infusions at Week 0 (Day 1) and Week 2 (Day 15), with the subsequent second- and third-courses given as a single 600 mg infusion at Weeks 24 and 48.
Study NCT04877457 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered at Week 0 (Day 1) and Week 2 (Day 15), with the subsequent second- and third-courses given at Weeks 24 and 48.
Study NCT04750902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8.0% Arginine Dentifrice
Description: Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study
Study NCT03696563 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated oxygen administration - FreeO2
Description: The adjustment of the oxygen flow will be made by the FreeO2 system, an automated titration of oxygen flow every second to reach the SpO2 target. The SpO2 target will be set at 90% in COPD patients and 94% in trauma patients.
Study NCT03696563 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard administration of oxygen flow
Description: The flow of oxygen will be administered according to the usual protocol during the transport and until transfer to the emergency departement.
Study NCT05339451 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood biomarkers
Description: Blood biomarkers in plasma and serum.
Study NCT00488605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone, Vinblastin, 6-mercaptopuroine
Description: Initial Therapy:Prednisone- by mouth 3 times/day daily as a 4-week course, then gradually decreased over 2 more weeks. Vinblastine-IV (into a vein)1 day/week for 6 weeks. Patients w/o evidence of active disease at this time will proceed to continuation therapy. If disease is improved or unchanged, pts. will receive additional therapy with: Prednisone- 3 divided doses by mouth for 3 days every week, from week 7-12. Vinblastine- IV 1day/week for 6 more weeks. If the disease is gone or better after this additional therapy continuation will begin. Continuation Therapy: 6-MP:by mouth daily until the end of month 12. Prednisone in 3 doses daily day 1-5 every 3 weeks until the end of month 12. Vinblastine IV day 1 every 3 weeks until the end of month 12.
Study NCT00488605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin, Methotrexate, Vinblastine, Prednisone
Description: Initial Therapy:Prednisone-by mouth 3x/day daily as a 4-week course then gradually decreased over 2 more weeks. Vinblastine- IV 1 day/week for 6 weeks. Methotrexate-a 24 hour IV infusion day 1 of weeks 1, 3, and 5, followed by leucovorin.The drug will be given by mouth. Pts w/o evidence of active disease at this time will proceed to continuation therapy. Pts whose disease is improved or unchanged will receive additional therapy w/:Prednisone- 3 divided doses, days 1-3 weekly from week 7-12. Vinblastine IV 1day/week for 6 more weeks. Methotrexate-a 24 hour IV infusion day 1 of week 7, 9, and 11, followed by leucovorin. If the disease is gone or better after this additional therapy continuation will begin. Continuation Therapy: 6-MP by mouth daily until the end of month 12. Prednisone- 3 doses daily days 1-5 every 3 weeks until the end of month 12. Vinblastine IV day 1 every 3 weeks until the end of month 12. Methotrexate by mouth once weekly until the end of month 12.
Study NCT05077046 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ergonomic handwriting pen
Description: An ergonomic handwriting pen called AWP-pen designed to reduce perceived muscle fatigue, finger tip pressure and discomfort during handwriting activities.
Study NCT06390176 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG powder
Description: Lactobacillus rhamnosus GG powder (PROBIOTICS Powder, USA) contained no less than 5×10\^8 CFU viable cells of Lactobacillus rhamnosus GG as the active ingredient.
Study NCT06390176 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-containing tablets
Description: Starch preparations that look and taste like Lactobacillus rhamnosus GG powder
Study NCT06390176 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiotherapy
Description: One of the inclusion criteria for the study was that patients with squamous carcinoma of the head and neck (including nasopharyngeal carcinoma) needed to receive either radiotherapy alone or simultaneous radiotherapy and chemotherapy, with radiotherapy using intensity-modulated radiotherapy techniques.
Study NCT06390176 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: One of the inclusion criteria for the study was that patients with squamous carcinoma of the head and neck (including nasopharyngeal carcinoma) needed to receive either radiotherapy alone or simultaneous radiotherapy and chemotherapy, with radiotherapy using intensity-modulated radiotherapy techniques.
Study NCT05606341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CpG1018
Description: 0.1 mg/kg dose administered via subcutaneous injection.~TLR9 agonist supplied by Dynavax Technologies Inc.
Study NCT05606341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CpG1018
Description: 0.25 mg/kg dose administered via subcutaneous injection.~TLR9 agonist supplied by Dynavax Technologies Inc.
Study NCT05606341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CpG1018
Description: 0.5 mg/kg dose administered via subcutaneous injection.~TLR9 agonist supplied by Dynavax Technologies Inc.
Study NCT05606341 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile saline injection supplied by the NYU Investigational Pharmacy.
Study NCT06235489 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Palfique Bulk Flow
Description: removal of caries in primary molars and placement of restorative materials
Study NCT06235489 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Palfique Bulk Flow
Description: removal of caries in primary molars and placement of restorative materials